Despite the large number of known partial D alleles, a relevant portion of anti-D immunizations is still occurring in individuals who did not carry any known partial D. 7-9 Thus, the characterization of the unknown alleles underlying such case reports is remaining important.
Introduction
Anti-D immunizations may occur in "partial D" carriers. This designation relates to more than 30 alleles differing in molecular structure, phenotype, population frequency, and lenience to anti-D production. 1 The molecular bases were gene conversions, 2 single missense mutations in the exofacial protein segments, 3 and multiple missense mutations dispersed throughout the RhD protein. 4 A partial D needs to be considered for transfusion strategies if its carriers are frequent, easily anti-D immunized, and likely to receive D-positive units in the case of transfusion. D category VI 5 is the classical example. In several countries, typing methods 6 were introduced that assured D-negative transfusion and anti-D prophylaxis for DVI mothers to prevent anti-D immunizations. Despite the large number of known partial D alleles, a relevant portion of anti-D immunizations is still occurring in individuals who did not carry any known partial D. [7] [8] [9] Thus, the characterization of the unknown alleles underlying such case reports is remaining important.
Study design Blood samples with anti-D
Two D-positive samples (RIR-2 from Bern, Switzerland; RIR-3 from Bavaria, Germany) with anti-D were referred to our laboratory to elucidate the cause of anti-D immunization. Later, 1 additional blood sample (RIR-41 from Denmark) and 2 DNA samples (RIR-7, RIR-8 from Austria) were referred to the Rhesus Immunization Registry (RIR) because of anti-D in these D-positive probands. The Danish proband RIR-41 had an Austrian grandfather.
RHD nucleotide sequencing
DNA was handled as described previously. 10 The 10 RHD exons were sequenced by an RHD allele-specific method 11 in the 2 index samples (RIR-2, RIR-3). In the remaining samples, exon 7 was sequenced only.
PCR-SSP
A polymerase chain reaction with sequence-specific priming (PCR-SSP) to confirm or detect the 1063GϾA substitution in DNB was devised as modular extension of a PCR-SSP system previously developed for RHD typing. 10, 12 Specific primers were re77 (TCTCCACAGCTCCATCATGGG) and DNBb (CAGTGACCCACATGCCATTACT) at a concentration of 3.5 mol; HGH control primers were used at 0.75 mol. . D epitopes were determined by agglutination, and antigen density and Rhesus index were determined by flow cytometry as previously described. 13 DIV type III 13 and DNU 14 controls derived from donors in Baden-Württemberg, Germany. 17 Phenotype frequencies for CcDee were compared using the Fisher exact test for a 4 ϫ 2 contingency table; for this calculation the 500 D-positive samples in Ticino were inferred to comprise 187 CcDee samples.
Immunohematology

Population screens for DNB
Nomenclature
The name DNB derived from DNU-like and Bayern (Bavaria, Germany) or Bern, because DNB was similar to DNU, 14 whose point mutations were closely adjacent.
Results and discussion
Molecular structure
The molecular structure of 2 D-positive samples with anti-D (RIR-2, RIR-3) was determined by RHD-specific sequencing from genomic DNA. In RHD exon 7, a single G to A exchange at position 1063 was detected that resulted in a Gly to Ser substitution at codon 355. The affected amino acid was located in the exofacial loop 6, adjacent to the mutations observed in DII (Ala to Asp at position 354) 14 and DNU (Gly to Arg at position 353). 14 The nucleic acid and amino acid sequence data were deposited in EMBL/GenBank/DDBJ under accession number AJ417868.
Immunohematology
In routine D typing, both DNB samples typed as CcDee without noticeable weakening of the antigen D. All 9 monoclonal anti-Ds of a commercial partial D classification kit (D-Screen) were reactive. An antigen density of 5908 antigens per cell and a Rhesus index 13, 18 (RI) of 0.02 were determined in RIR-2. These results were comparable to those obtained with a DNU sample (8073 antigens per cell, RI 0.06) and a CcDee DIV type 3 sample (4544 antigens per cell, RI 0). The D epitope pattern was determined for both index samples and was unique ( Table 1) : 6 of 83 anti-Ds tested did not agglutinate DNB, indicating a loss of epitopes epD6 and epD31 as well as part of epD18 and epD23. The crossmatch with DNU red cells was faintly positive; there are no DII red cells available anymore.
Population frequencies
We screened random samples of CcDee blood donors in 4 European populations (Table 2) . With the exception of Danes, DNB was found frequently. The highest frequency was observed in the Ticino population. DNB was the most frequent partial D in whites described so far; its frequency even exceeded that of DVII. 19 Further testing of other populations may be of potential benefit.
Including the probands with anti-D, we presented 12 unrelated carriers of DNB who were whites of Central Europe; the only Danish proband had an Austrian grandfather, from whom he may have inherited the DNB allele. All DNB probands were of CcDee phenotype. The CDe haplotype association was further corroborated by testing the parents of the Danish proband RIR-41, who inherited his DNB allele from his CCDee father.
Anti-D immunization
Including the 2 index probands, 5 cases of allo-anti-D immunization submitted to the Rhesus Immunization Registry occurred in DNB probands (RIR-2, RIR-3, RIR-7, RIR-8, and RIR-41). 20 These cases represented a sizable fraction of the 32 confirmed allo-anti-D immunizations reported to this registry until February 2002. Although any Rhesus-positive blood sample with anti-Dwith or without known Rhesus variant-may be sent to the registry for analysis, no other RHD allele was involved in a similar number of cases. Two additional carriers of DNB with anti-D were from Slovakia (Dr Martin Pisacka, personal communication, 1999) and from Germany (submitted as RIR-49 after we had finished the data analysis).
Anti-D titers ranged from 4 to 128, indicating that DNB carriers were generally able to produce strong anti-D. However, no clinical data like signs of transfusion reactions or hemolytic disease of the newborn were reported. In concordance with the assumption that 
N/A indicates not applicable; ϩ, a normal or weak positive result; and Ϫ, a negative result. *Pattern is as described previously by Lomas et al 24 (1-9) and Scott 21 (1-37). †A complete listing of the antibodies was published previously 13 ( Table 2 ). The following antibodies failed to agglutinate DNB: LOR17-6C7 (epD6), P3F20 (epD18), HIRO-7, HIRO-8 (epD23), NAU6-1G6, and NOU (epD31). In addition, the reactivity of the following anti-Ds differed from that of the majority assigned to the respective epitope: D-90/7, SAL20-12D5, LHM50/2B, BIRMA-DG3 (epD15/16), as well as VOL-3F6 (epD20/21) did not agglutinate DIV type 3; LHM77/64, BIRMA-D6 (epD23), and NAU6-4D5 (epD36) did not agglutinate DNU.
‡The DNB pattern was established with samples RIR-2 and RIR-3 and the DNU pattern with red cells of the original DNU donor. 14 The DIV type 3 data are a reevaluation of the original pattern using a CcDee DIV type 3 donor from our local population.
§The results depicted for D category II were determined by Scott 21 and are shown for comparison.
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Impact on typing strategies
The repeated observations of anti-D immunizations probably reflected the combination of a high population frequency with a phenotype that triggered D-positive transfusions and with a moderate anti-D immunization potential. Hence, we recommended D-negative transfusions if a recipient is known to carry a DNB phenotype.
A serologic recognition of DNB would be demanding because it has a normal antigen density and is agglutinated by most anti-Ds, including almost all commercial anti-D typing reagents. All tested high-affinity monoclonal IgM anti-Ds that did not bind DVI but that agglutinated most weak D phenotypes 13, 21 agglutinated DNB also (Table 1) . Therefore, a serologic strategy for detecting DNB would have to rely on a separate anti-D especially introduced to discriminate DNB from normal D. By careful selection of this third antibody (eg, HIRO-7 or HIRO-8), the strategy could be tuned to discriminate also DII, DIV, and R 0
Har from normal D. 21 Such a major change in D typing would be costly and might induce uncertainties that outweigh the benefit by far. The anti-D immunization risk in DNB carriers may safely be estimated to be lower than 1% per D-positive transfusion. This immunization index was less than known for anti-K and anti-c 22 but may be comparable to that of anti-Fy(a) and anti-Jk(a).
Genotyping strategies are increasingly utilized for blood grouping 23 and may be devised to meet predefined specificity criteria. For example, RHD PCR in whites may be tuned to a specificity of greater 0.9999 and allows the identification of D-positive units missed by routine serology. 10 Likewise, DNB or DIIIa alleles may be detected specifically without any limitations imposed by the lack of suitable monoclonal anti-D. Because the frequency of partial D with relevant anti-D immunization risk is low in whites, their D-negative transfusion would not compromise the D-negative blood supply. Hence, a specific recognition and D-negative transfusion strategy for DNB may be perceived advantageous and become feasible with genotyping strategies in the future. For personal use only. on July 16, 2017 . by guest www.bloodjournal.org From
